Effect of Vancomycin Administration Method on Achieving and Maintaining Its Serum Concentrations In Intensive Care Patients

1. Cataldo MA et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections, systematic review and meta-analysis. // J Antimicrob Chemother, 2012; 67(1):17-24.10.1093/jac/dkr44222028203Search in Google Scholar

2. Devabhakthuni S. Antibiotic Pharmacokinetic Monitoring. // Published 2011. Retrieved on May 22, 2013 from www.ashp.org/DocLibrary/MemberCenter/NPF/2011Pearls/Antibiotic-Pharmacokinetic-Monitoring.aspxSearch in Google Scholar

3. Di Filippo A et al. Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. // Chemotherapy, 1998; 44(1):63-68.10.1159/0000070929444411Search in Google Scholar

4. Hidayat LK et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections, efficacy and toxicity. // Arch Intern Med, 2006; 166:2138-2144.10.1001/archinte.166.19.213817060545Search in Google Scholar

5. Ibrahim NS et al. Time to Achieving Target Concentration of Vancomycin, Intermittent Infusion versus Continuous Infusion of Vancomycin in Intensive Care Unit. // Published 2011. Retrieved on March 22, 2013 from http://www.kck.usm.my/husm/pharmacy/images/penerbitanSearch in Google Scholar

6. Jeffres MN et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with healthcare-associated methicillinresistant Staphylococcus aureus pneumonia. // Clin Ther, 2007; 29:1107-1115.10.1016/j.clinthera.2007.06.01417692725Search in Google Scholar

7. Law Min C, Bourne R. Continuous Vancomycin Infusion Guidelines in Critical Care. // Sheffield Teaching Hospitals NHS Foundation Trust Guidelines, 2012.Search in Google Scholar

8. Lodise TP et al. Larger vancomycin doses (≥4 grams/day) are associated with an increased incidence of nephrotoxicity. // Antimicrob Agents Chemotherapy, 2008; 52:1330-1336.10.1128/AAC.01602-07229253618227177Search in Google Scholar

9. Nguyen M et al. Nephrotoxicity associated with high dose vs standard dose vancomycin therapy. // In: 47th Interscience Conference on Antimicrob Agents Chemotherapy. 2007; Chicago, IL, September 2007.Search in Google Scholar

10. Pauly DJ et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. // Pharmacotherapy, 1990; 10:378-382.Search in Google Scholar

11. Pea F et al. Prospectively validated dosing nomograms for maximizing pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. // Antimicrob Agents Chemotherapy, 2009; 53(5):1863-1867.10.1128/AAC.01149-08268151519223642Search in Google Scholar

12. Rello J et al. Pneumonia caused by oxacillinresistant Staphylococcus aureus treated with glycopeptides. // Crit Care Med, 2005; 33(9):1983-1987.10.1097/01.CCM.0000178180.61305.1DSearch in Google Scholar

13. Roberts JA et al. Better outcomes through continuous infusion of time dependent antibiotics to critically ill patients? // Curr Opin Crit Care, 2008; 14:390-396.Search in Google Scholar

14. Roberts JA, Lipman J. Antibacterial dosing in intensive care, pharmacokinetics, degree of disease and pharmacodynamics of sepsis. // Clin Pharmacokinet, 2006; 45:755-773.10.2165/00003088-200645080-0000116884316Search in Google Scholar

15. Rybak MJ et al. Vancomycin Therapeutic Guidelines, A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. // Clin Infect Dis, 2009; 49:325-327.10.1086/60087719569969Search in Google Scholar

16. Rybak MJ, Lomaestro B. Therapeutic monitoring of vancomycin in adult patients, A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. // AJHP, 2009; 66:82 - 98.Search in Google Scholar

17. Rybak MJ et al. Nephrotoxicity of vancomycin alone and with an aminoglycoside. // J Antimicrob Chemother, 1990; 25:679-687.10.1093/jac/25.4.6792351627Search in Google Scholar

18. Vuagnat A et al. High dose vancomycin for osteomyelitis, continuous vs intermittent infusion. // J Clin Pharm Ther, 2004; 29(4):351-357.10.1111/j.1365-2710.2004.00572.x15271102Search in Google Scholar

19. Wysocki M et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections, prospective multicenter randomized study. // Antimicrob Agents Chemotherapy, 2001; 45(9):2460-2467.10.1128/AAC.45.9.2460-2467.20019067811502515Search in Google Scholar